



PATENT  
Customer No. 22,852  
Attorney Docket No. 02481/1773

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
)  
Anuschirwan PEYMAN et al. ) Group Art Unit: 1625  
)  
Application No.: 10/004,422 ) Examiner: C. Chang  
)  
Filed: December 6, 2001 )  
)  
For: NEW GUANIDINE AND AMIDINE )  
DERIVATIVES AS FACTOR Xa )  
INHIBITORS )

*for fee  
purpose only  
JRP  
4/20/04*

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

AMENDMENT

In reply to the Office Action dated April 18, 2003, please amend the application  
as indicated on the following pages:

04/21/2004 FPATTERS 00000001 060916 10004422

01 FEB 12 2004 468.00 DA  
HENDERSON  
FARABOW  
GARRETT &  
DUNNELL

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

To establish a *prima facie* case of obviousness, the prior art references when combined must teach or suggest all the claim elements. M.P.E.P. § 2143 (8<sup>th</sup> ed. 2001). Applicants respectfully submit that the Examiner has failed to establish this requirement.

Both of these references were discussed in detail above. Applicants respectfully submit that, for the reasons discussed above, the combination of references fails to teach or suggest all the claim elements. Specifically, neither reference teaches or suggests that claimed compound of formula (I) wherein R<sub>0</sub>, Q, Q', X, and D are as presently defined.

### CONCLUSION

In view of the foregoing amendments and remarks, Applicants respectfully request the reconsideration of this application and the timely allowance of the pending claims.

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: August 12, 2003

By: 

Carol L. Cole  
Reg. No. 43,555

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com